Spontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal

Takayuki Goto1, Kiichi Hatano2, Nobuhiro Kanemura1

  • 1Department of Hematology, Chuno Kosei Hospital, Gifu, Japan.

Journal of Hematology
|December 19, 2024
PubMed

Insights

Methotrexate-associated lymphoproliferative disorder (MTX-LPD) can manifest as aggressive Plasmablastic Lymphoma (PBL). Discontinuation of methotrexate led to remission in a 75-year-old woman, highlighting the importance of considering MTX-LPD in PBL diagnosis.

Area of Science:

  • Oncology
  • Pathology
  • Immunology

Background:

  • Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma.
  • PBL primarily affects immunocompromised and elderly individuals.
  • Methotrexate (MTX) is associated with lymphoproliferative disorders (LPDs).

Observation:

  • A 75-year-old woman presented with oral ulcers and lung masses.
  • Biopsy confirmed Plasmablastic Lymphoma (PBL) with specific B-cell markers and Epstein-Barr virus.
  • The patient had a history of methotrexate use for rheumatoid arthritis and was HIV-negative.

Findings:

  • The patient's condition was diagnosed as methotrexate-associated lymphoproliferative disorder (MTX-LPD) presenting as PBL.
  • Discontinuation of methotrexate resulted in the resolution of oral ulcers within one month.
  • Lung lesions showed a decrease in size over time following MTX withdrawal.

Implications:

  • MTX-LPD should be considered in the differential diagnosis of PBL, particularly in patients with MTX exposure.
  • Withdrawal of methotrexate alone can lead to remission in some MTX-LPD cases.
  • Careful consideration of therapeutic interventions is crucial, as MTX-LPD may resolve spontaneously or require additional treatment if progressive.